Skip to main content
. 2023 Jul 23;30(2):e14366. doi: 10.1111/cns.14366

FIGURE 10.

FIGURE 10

PSMD9 promotes glioblastoma progression and reverses the anti‐glioblastoma effect of panobinostat in vivo. (A and B) In vivo bioluminescence imaging and quantification of xenografts derived from lentivirus‐infected LN229 shNC and shPSMD9 cells at the indicated time points. (C and D) Weight curve and Kaplan–Meier curves of survival time for nude mice implanted with LN229 shNC and shPSMD9 cells at the indicated time points. (E and F) Representative images of IHC of PSMD9, CDK1 and Vimentin in xenograft sections (scale bar, 20 μm). (G and H) Bioluminescence imaging and quantification of xenografts derived from the LN229 PSMD9‐NC group, PSMD9‐NC panobinostat treatment group and lentivirus‐infected PSMD9‐OE + panobinostat treatment group at the indicated time points. (I) Kaplan–Meier analysis of survival time for nude mice at the indicated time points. (J and K) Representative images of IHC of PSMD9, CDK1 and Vimentin in xenograft sections (scale bar, 20 μm). Comparisons between two independent samples and among multiple samples were performed using two‐tailed t tests and one‐way ANOVA, respectively. Error bars indicate at least three independent experiments, and data are shown as the mean ± SD. n.s = no significance. *p < 0.05, **p < 0.01 and ***p < 0.001.